HiLung was founded in 2020 to dramatically accelerate respiratory drug discovery and development, based on our pioneering cell differentiation technologies which can mass-produce respiratory cells from human stem cells, including human iPSCs (induced pluripotent stem cells) –unprecedented industry-scale yield of which positions us at the forefront of R&D in respiratory cell & organoid biology. All through our leading efforts, we strive to contribute to a future where all respiratory diseases can be cured and "Everybody Is Happily Inspiring".